Exclusive partnership expands access to single-cell analysis in China

Sphere Bio has announced a major step forward in its Asia-Pacific expansion strategy by appointing Redbert Biotechnology as its exclusive distribution partner in China. The collaboration is set to increase access to the company’s picodroplet-based single-cell analysis platforms, including the recently launched Cyto-Mine® Chroma multiplexing system.

The agreement aims to meet rising demand in the Chinese market for advanced tools supporting antibody discovery, cell line development, and cell therapy research. Redbert Biotechnology brings a strong regional footprint, with offices across major Chinese cities, and extensive experience working with CDMOs, CROs, and academic institutions.

To support this growth, Sphere Bio has also appointed Johnathan Fu as China Distribution Manager. With nearly two decades of experience in life science instrumentation sales – including roles at 10x Genomics, Roche Diagnostics, and Bio-Rad – Fu will lead local commercial strategy and customer support. He reports to Jay Manikandan, Sphere Bio’s VP of Commercial for APAC.

Dale Levitzke, CEO of Sphere Bio, said: “China is a key market for innovation in life sciences. This partnership, along with our regional expansion efforts, ensures we can better serve researchers with cutting-edge solutions and dedicated local support.”

Wei Zhang, CEO of Redbert Biotechnology, added: “We are excited to introduce Sphere Bio’s technology to our customers, particularly the Cyto-Mine Chroma platform. It has the potential to significantly advance research across the region.”

Johnathan Fu, China Distribution Manager, added: “I’m excited to help bring Sphere Bio’s technology to more researchers in China. Our goal is to make adoption seamless and ensure customers get the support they need to accelerate discovery.”

More information online